The purpose of the study is to investigate the safety and feasibility of using this treatment method in patients aged 18 to 75 who have been diagnosed with grade IV glioblastoma. Participants will receive the treatment during surgery, and the study will monitor how well the treatment is tolerated and determine the best light dose to use in future trials. The study will also look at how long it takes for the disease to progress after the treatment and gather feedback on the usability of the device used in the procedure.

Throughout the study, participants will be closely monitored for any side effects or adverse events. The study aims to provide valuable information on the potential benefits and risks of using Pentalafen and Heliance in treating glioblastoma, which could lead to improved treatment options for patients with this challenging condition.

Participants in the study will be randomly assigned to receive either lomustine by itself or the combination of lomustine and bevacizumab. The study will monitor the overall survival of participants, which means the length of time they live after starting the treatment. Additionally, the study will look at how long patients remain free from cancer progression, the response to the treatment, and the safety of the combination therapy compared to lomustine alone.

The trial is expected to last for several years, with the goal of gathering enough information to determine the best treatment approach for recurrent glioblastoma. By participating in this study, researchers hope to find more effective ways to manage this challenging disease and improve the quality of life for those affected by it.

The purpose of this research is to determine how well tovorafenib works in treating these types of tumors and to understand its safety in patients aged 6 months to 25 years. The medication is specifically designed to reach the central nervous system (brain and spinal cord) and works by blocking certain proteins that can cause tumor growth.

During the study, participants will receive tovorafenib daily by mouth. The treatment may continue for up to 72 months, depending on how well it works for each patient. Doctors will regularly check the size of tumors using imaging tests and monitor patients for any side effects that may occur during treatment.

Participants in the study will take Vinorelbine three times a week and Propranolol daily. The study will monitor how well participants tolerate the treatment and will assess any side effects. The trial will also evaluate how effective the treatment is in controlling the cancer over a period of six months. The study aims to find the best dose that balances effectiveness with minimal side effects.

This trial is important for finding new ways to treat children and teenagers with difficult-to-treat cancers. By combining these two medications, researchers hope to improve outcomes for patients who have limited treatment options. The study will provide valuable information on the safety and potential benefits of this treatment combination.

The study is divided into two phases. In the first phase, the focus is on understanding how safe and tolerable the combination of Bortezomib and Temozolomide is for patients. This phase will help determine the best dose of each medication when used together. In the second phase, the study will evaluate how effective the combination is in treating the cancer. This includes looking at how long patients live without the cancer getting worse and their overall survival time. The study will involve a total of 63 patients, with 10 in the first phase and 53 in the second phase.

Throughout the study, patients will undergo regular assessments, including MRI scans and neurological exams, to monitor the response of the tumor to the treatment. The study will also explore new markers in the blood and tumor tissue that might indicate how well the treatment is working. The trial aims to provide valuable insights into the potential benefits of combining Bortezomib with Temozolomide for patients with recurrent Grade IV glioma.

The study will determine which treatment is more effective at shrinking or controlling the tumor. Patients will be randomly assigned to receive either tovorafenib tablets or oral suspension taken by mouth, or standard chemotherapy medications given through an intravenous line (a small tube inserted into a vein). The study will measure how well tumors respond to treatment and how long patients remain free from tumor growth.

Doctors will regularly monitor patients using brain scans and medical examinations to track the tumor’s response to treatment. The study will continue for several years to gather long-term information about how well each treatment works and how it affects patients’ health over time. This research aims to help determine the most effective treatment option for children and young people with this specific type of brain tumor.

The purpose of this study is to evaluate how well these combination therapies work in patients with DMGs. The study will be conducted in different phases, where participants will receive the combination of ONC201 and Paxalisib at various stages of their treatment journey. This includes those who are newly diagnosed, those who have completed radiation therapy, and those whose tumors have returned. The study aims to see if these treatments can help patients live longer without their disease getting worse.

Participants in the study will take the medications in capsule form, which means they will swallow them. The study will monitor the participants over time to assess the effectiveness of the treatment. The goal is to determine if the combination of ONC201 and Paxalisib can improve the outcomes for patients with these challenging brain tumors. The study is expected to continue until early 2026, with the hope of finding a more effective treatment option for those affected by DMGs and DIPGs.

Participants in the study will be randomly assigned to receive either the ONC201 medication or a placebo, which looks like the medication but does not contain the active ingredient. This is done to compare the effects of the actual medication against no treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results. The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the tumor’s response to the treatment.

The main goals of the study are to see if ONC201 can help improve overall survival and delay the progression of the tumor. Researchers will also look at other factors, such as any side effects experienced by participants and changes in their quality of life. The study aims to provide valuable information on whether ONC201 can be a beneficial treatment option for people with H3 K27M-mutant diffuse glioma after they have completed radiation therapy.